US Healthcare Market Access and Pricing Pressure Analysis

This document is a research report that analyzes the intensifying access and pricing policy risks within the US healthcare market. It outlines how these risks are impacting various players across the healthcare value chain, with a particular focus on managed healthcare companies, which are identified as facing the greatest exposure to potential material impacts. The report details the shifting regulatory scrutiny that has traditionally targeted biopharma companies but is now increasingly directed towards managed healthcare entities. It presents findings from Sustainalytics’ ESG Risk Ratings data, which indicate that while managed healthcare companies are at risk, they are also well-positioned to navigate these challenges due to their effective management of access to services. The report further discusses the implications for pharmaceutical and biotechnology companies, which face significant risks that could affect patient access and affordability. Additionally, it highlights the broader societal and ethical considerations surrounding access to basic healthcare services, emphasizing the importance of addressing these issues within the context of ongoing policy changes.